Study on Volrustomig Alone or with Other Cancer Drugs for Advanced Solid Tumors

Inclusion Criteria

• Must be 18 years or older.
• Must provide a tumor sample to check for a specific protein (PD-L1).
• Must have a measurable tumor based on specific medical criteria.
• Must be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must have a life expectancy of at least 12 weeks.
• Must have good organ and bone marrow function.
• Must weigh more than 35 kg (about 77 pounds).
• Must be able to give informed consent.
• For cervical cancer patients: Must have experienced disease progression after standard treatment and have had 1-2 prior treatments.
• For head and neck cancer patients: Must have documented HPV status and specific medical history related to the cancer.
• For head and neck cancer patients in the combination therapy group: Must meet specific medical criteria related to the cancer.

Exclusion Criteria

• Have spinal cord compression.
• Have brain metastases unless they are stable and not requiring steroids.
• Have certain types of cancer not included in the study.
• Have not recovered from side effects of previous cancer treatments.
• Have had recent radiotherapy or have contraindications to certain chemotherapy drugs.
• Have a history of another primary cancer unless it was treated and inactive for at least 2 years.
• Have certain infections or autoimmune disorders.
• Are candidates for curative therapy.
• Have used immune therapy or immunosuppressive medication recently.
• Have received other cancer treatments recently.
• Have had major surgery recently.
• Have received a live vaccine recently.
• Have allergies to the study drugs.